​Gedeon Richter Plc. ("Richter") announces today that with effect from 18 September 2018 the Romanian National Agency for Medicines and Medical Devices (NAMMD) granted the licence to operate of Pharmafarm SA ("Pharmafarm"), Richter's wholesaler subsidiary again. Most of our warehousing facilities have already re-obtained their licence.

​Gedeon Richter Plc. ("Richter") today announced that it has entered into a license and distribution agreement with L.D. Collins & Co. Limited
("L.D. Collins"), a UK based company, to commercialize its 400mg progesterone containing assisted reproduction technology (ART) product, Cyclogest^® in  27 EU countries. Marketing authorizations have already been granted in the above territory. Following the transfer of the marketing authorization holder to Richter, the launch of the product is expected to be executed from early 2019.

​Gedeon Richter Plc. (hereinafter: "Richter") and Mithra Pharmaceuticals (hereinafter: "Mithra") today announced that they have entered into a license and supply agreement to commercialize Estelle^®, a combined oral contraceptive, containing 15 mg estetrol (E4) / 3 mg drospirenone.  Richter is going to commercialize the product under a different brand name. The product is considered a novel oral contraceptive with natural, native estrogen acting selectively in tissues combined with drospirenone's non contraceptive benefits. The geographic scope of the agreement covers Europe and Russia.